

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A glycopeptide of the formula  $A_1-A_2-A_3-A_4-A_5-A_6-A_7$ , [SEQ ID NO:1] ~~in which each dash represents a covalent bond; wherein each of the groups  $A_1$  to  $A_7$  comprises an  $\alpha$ -amino acid residue, whereby (i) the group  $A_4$  is linked to an amino group on the group  $A_2$ , (ii) each of the groups  $A_2$ ,  $A_4$  and  $A_6$  bears an aromatic side chain, which aromatic side chains are cross linked together by two or more covalent bonds, and (iii) the group  $A_7$  bears a terminal carboxyl, ester, amide, or N-substituted amide group~~ the heptapeptide structure of naturally occurring vancomycin;

and wherein the group  $A_4$  is linked via a glycosidic bond to a disaccharide having a glucose residue directly attached to said  $A_4$  residue, wherein said glucose residue bears an N-substituted aminohexose residue and at least one substituent of the formula YXR, attached to the C-6 position of said glucose;

wherein the group Y is a single bond, O,  $NR_1$  or S; the group X is O,  $NR_1$ , S,  $SO_2$ ,  $C(O)O$ ,  $C(O)S$ ,  $C(S)O$ ,  $C(S)S$ ,  $C(NR_1)O$ ,  $C(O)NR_1$ , or halo (in which case Y and R are absent); and  ~~$R$ ,  $R_1$ ,  $R_2$ , and  $R_3$~~   $R$  and  $R_1$  are independently hydrogen, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl or arylsulfonyl; and any pharmaceutically acceptable salts thereof; provided that at least one of the substituents of the formula YXR is not hydroxyl; X and Y are not both O; X and Y are not S and O, or O and S, respectively; and if two or more of said substituent are present, they can be the same or different.

Claims 2-4 (Cancelled).

5. (Previously Presented) The glycopeptide of claim 1 in which at least one of said substituent is YXR wherein Y is a single bond and X is O,  $NR_1$ , S or  $SO_2$ .

6. (Original) The glycopeptide of claim 5 wherein X is  $NR_1$ .

Claims 7-25 (Cancelled).

26. (Previously Presented) The glycopeptide of claim 5 in which the N-substituted aminohexose residue bears at least one of said substituent.

27. (Previously Presented) The glycopeptide of claim 6 in which the N-substituted aminohexose residue bears at least one of said substituent.

Claims 28-101 (Cancelled)

102. (Currently Amended) A vancomycin glycopeptide antibiotic bearing at least one disaccharide group, said disaccharide group comprising two saccharide groups, a first of said saccharide groups bearing at least one amino group, and a second of said saccharide groups linked directly to said glycopeptide bears at least one substituent of the formula YXR, at the C-6 position of said saccharide, in which the group Y is a single bond, O, NR<sub>1</sub> or S; the group X is O, NR<sub>1</sub>, S, SO<sub>2</sub>, C(O)O, C(O)S, C(S)O, C(S)S, C(NR<sub>1</sub>)O, C(O)NR<sub>1</sub>, or halo (in which case Y and R are absent); and ~~R, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub>~~ R and R<sub>1</sub> are independently hydrogen, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl or arylsulfonyl, provided that the substituents of the formula YXR is not hydroxyl; X and Y are not both O; X and Y are not S and O, or O and S, respectively; and if two or more of said substituents are present, they can be the same or different, or a pharmaceutically acceptable salt thereof.

103. (Currently Amended) The vancomycin glycopeptide antibiotic of claim 102 wherein the second of said saccharide groups is glucose modified to bear at least one substituent which is not hydroxyl at the C6 position of said glucose.

104. (Canceled)

105. (Currently Amended) The vancomycin glycopeptide antibiotic of claim ~~104~~ 103 wherein said at least one substituent which is not hydroxyl at the C6 position of said glucose is amino.

106. (Currently Amended) The vancomycin glycopeptide antibiotic of claim 105 wherein the first of said saccharide groups bears at least one substituted amino group.

107. (Currently Amended) The vancomycin glycopeptide antibiotic of claim 106 wherein said amino group is NR<sub>1</sub>H wherein R<sub>1</sub> bears one or more alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic or substituted heterocyclic groups.

Claims 108-115. (Cancelled)

116. (Currently Amended) The vancomycin glycopeptide antibiotic of claim 112 wherein said at least one substituent which is not hydroxyl is amino.

117. (New) A vancomycin glycopeptide comprising:  
a glucose residue substituted at the C-6 position with at least one substituent of the formula YXR;

wherein the group Y is a single bond, O, NR<sub>1</sub> or S; the group X is O, NR<sub>1</sub>, S, SO<sub>2</sub>, C(O)O, C(O)S, C(S)O, C(S)S, C(NR<sub>1</sub>)O, C(O)NR<sub>1</sub>, or halo (in which case Y and R are absent); and R and R<sub>1</sub> are independently hydrogen, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl or arylsulfonyl; and any pharmaceutically acceptable salts thereof; provided that at least one of the substituents of the formula YXR is not hydroxyl; X and Y are not both O; X and Y are not S and O, or O and S, respectively; and if two or more of said substituent are present, they can be the same or different.